Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 17/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12373566 | 0.89 | S1PR1 (0.40) | S1PR1S1PR3ALDH1A1CYP2C19 | |
| SCHEMBL12373681 | 0.89 | S1PR1 (0.44) | S1PR1S1PR3PPARGALDH1A1 | |
| SCHEMBL12373665 | 0.89 | S1PR1 (0.39) | S1PR1S1PR3PPARGALDH1A1 | |
| SCHEMBL12373765 | 0.86 | S1PR1 (0.45) | S1PR1S1PR3ALDH1A1SMN1; SMN2CYP2C19 | |
| SCHEMBL12373526 | 0.86 | S1PR1 (0.54) | S1PR1ALDH1A1SMN1; SMN2CYP2C19CYP3A4 | |
| SCHEMBL12373517 | 0.85 | S1PR1 (0.44) | S1PR1S1PR3ALDH1A1CYP2C19 | |
| SCHEMBL12373548 | 0.85 | S1PR1 (0.49) | S1PR1S1PR3ALDH1A1SMN1; SMN2CYP2C19 | |
| SCHEMBL12373672 | 0.85 | S1PR1 (0.45) | S1PR1CYP2C19CYP3A4CYP3A5 | |
| SCHEMBL12373762 | 0.85 | S1PR1 (0.38) | S1PR1PPARGCYP3A4CYP3A5 | |
| SCHEMBL12373464 | 0.85 | KDM4E (0.41) | S1PR1S1PR3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994204-B2 | Binding inhibitor of sphingosine-1-phosphate | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994204-B2 | Binding inhibitor of sphingosine-1-phosphate | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885PPARG 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.